Subscribe to our newsletter

Lytix Biopharma shall not pass on your contact information to third parties or use the contact information provided for other purposes than keeping you informed about company news.

Please make sure to confirm your adress (a confirmation email will be send to you shortly) and to accept the Lytix Biopharma newsletter, if it is not delivered directly to your inbox.
September 01, 2010:
- Approval to start Phase IIa clinical trial with Lytixar™ (LTX-109)
Read more
Oslo, Norway and Seoul, Korea, June 09, 2010:
- Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial
Read more
May 20, 2010:
- Update on the Phase I clinical trials of Oncopore™ (LTX-315) for the treatment of cancer.
Read more
May 20, 2010:
- Approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial
Read more
Go to news archive >